{"prompt": "['Date and Version No: 7 19/12/19', '6.2', 'Primary and Secondary Endpoints/Outcome Measures', 'Primary end point measures:', '1) Number of participants successfully recruited', '2) Percentage of participants able to successfully complete the CT program and all', 'assessments', '3) Percentage of participants with full bilateral data for CBFv', '4) Feasibility of randomisation to waiting list control', 'Secondary end points:', \"1) Change in cognition score as detected by the Addenbrooke's cognitive examination\", '(ACE-III)', '2) Change in functional status - Lawton IADL', '3) Change in mood - GDS-15', '4) Change in quality of life measure - DEMQOL', '5) Change in task activation increase in CBFv from baseline', 'CONFIDENTIAL', 'Page 21 of 57', 'The Cognition and Flow Study']['Date and Version No: 7 19/12/19', '7.', 'TRIAL PARTICIPANTS', '7.1', 'Overall Description of Trial Participants', '1) Participants with mild-moderate AzD', '2) Participants with MCI', '3) Healthy older adults', '4) Post-ischaemic stroke', '7.2 Inclusion Criteria', 'Study specific inclusion criteria will be as follows:', 'One of:', '1) Healthy controls will be free of any medical co-morbidity or medication that could', 'adversely affect cognition. Volunteers with well-controlled co-morbidities (i.e.', 'hypertension, diabetes, will be considered for inclusion)', '2) MCI as defined by NIA/AA 2011 and Petersen criteria', '3) AzD as defined by the NIA/AA 2011 criteria', '4) Ischaemic stroke within the last 12 months', 'And:', '5) Deficits will be mild to moderate as defined by Montreal Cognitive Assessment', \"(MoCA) score of >/=9 for all participants with MCI or Alzheimer's disease (32-34).\", '6) Willing to participate', '7) Capacity to consent to the study/personal consultee', '8) Patients on and off anti-dementia medications will be included', '(acetylcholinesterase inhibitors, glutamate receptor antagonists)', '9) Good understanding of written and spoken English', '10) Age >50 years (MCI, AzD, and healthy controls only)', '11) Access to the internet and a computer or laptop.', '7.3', 'Exclusion Criteria', 'Study specific exclusion criteria as follows:', 'CONFIDENTIAL', 'Page 22 of 57', 'The Cognition and Flow Study']['Date and Version No: 7 19/12/19', '1) Healthy controls with any medical co-morbidity or medication that could adversely', 'affect cognition, or poorly controlled medical co-morbidities (i.e. hypertension,', 'diabetes)', '2) Unwilling to take part', '3) Unable to consent/no personal consultee', '4) Major medical co-morbidity; severe heart failure (ejection fraction <20%),', 'significant carotid artery stenosis >50%), severe respiratory disease, major stroke', '(MCI and AzD groups only)', '5) Pregnancy, planning pregnancy, or lactating', '6) Inadequate bilateral TCD windows', '7) Participants already enrolled into other interventional studies', '8) Insufficient understanding of written and spoken English', '9) Age <50 years (MCI, AzD, and healthy controls only)', '10) No access to the internet and a computer or laptop.', 'CONFIDENTIAL', 'Page 23 of 57', 'The Cognition and Flow Study']\n\n###\n\n", "completion": "END"}